Join
Live feed
·
PRReleasevia Quantisnow
Arrowhead Pharmaceuticals Inc. logo

Arrowhead Pharmaceuticals Initiates Phase 1/2a Study of ARO-DIMER-PA – the First Dual Functional RNAi Therapeutic for the Treatment of Mixed Hyperlipidemia

ByQuantisnow·Wall Street's wire, on your screen.
ARWR· Arrowhead Pharmaceuticals Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ARWR (Arrowhead Pharmaceuticals Inc.) and more on Quantisnow.